Published in Vaccine Weekly, December 6th, 2000
In an invited presentation entitled "Autologous, hapten-modified vaccine in melanoma and other solid tumors," David Berd, MD, Thomas Jefferson University, Philadelphia, Pennsylvania, summarized results of trials in which M-Vax was administered to 37 stage IV melanoma patients who had undergone complete resection of metastatic tumors that had spread to various internal organs.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly